Search | Clinical Trials Finder

Conditions: Asthma
Interventions: Albuterol Spiromax, ProAir HFA, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 22
States / cities: Birmingham, Alabama • Little Rock, Alaska • Costa Mesa, California + 19 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: PT003, PT001, PT005; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 13
States / cities: Rancho Mirage, California • Colorado Springs, Colorado • Waterbury, Connecticut + 10 more

Conditions: Asthma
Interventions: BDA MDI, AS MDI; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 117
States / cities: Anchorage, Alaska • Gilbert, Arizona • Phoenix, Arizona + 93 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: UMEC/VI DPI, Placebo DPI, Albuterol/salbutamol MDI; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: Jasper, Alabama • Saint Charles, Missouri • Charlotte, North Carolina + 7 more

Conditions: Asthma, Bronchospasm, Shortness of Breath
Interventions: Virtual Teach to Goal, Brief Intervention; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 5 Years to 10 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI, Placebo to match budesonide/formoterol, tiotropium, Placebo to match FF/UMEC/VI, placebo to match tiotropium, ELLIPTA, MDI, HandiHaler; Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 729 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 40
States / cities: Gold River, California • Clearwater, Florida • DeBary, Florida + 31 more

Conditions: Asthma
Interventions: FF/UMEC/VI (100/31.25/25) mcg, FF/UMEC/VI (100/62.5/25) mcg, FF/UMEC/VI (200/31.25/25) mcg, FF/UMEC/VI (200/62.5/25) mcg, FF/VI (100/25) mcg, FF/VI (200/25) mcg, Fluticasone/salmeterol (FSC), Albuterol/salbutamol, ELLIPTA DPI, DISKUS DPI, METERED-DOSE INHALER (MDI); Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 2,436 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 99
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 89 more

Conditions: Type 1 Diabetes
Interventions: Tandem t:slim X2 with Control-IQ Technology Pro, Standard Care (SC), Tandem t:slim X2 with Control-IQ Technology V1.5; Device
Lead sponsor: Marc Breton; Other
Eligibility: 24 Months to 71 Months
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Stanford, California • Aurora, Colorado • Charlottesville, Virginia

Conditions: Chronic Obstructive Pulmonary Disorder
Interventions: BFF MDI 320/9.6 μg, BFF MDI 160/9.6 μg, FF MDI 9.6 μg, BD MDI 320 μg, Symbicort® TBH 400/12 μg BID; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 2,389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 83
States / cities: Athens, Alabama • Birmingham, Alabama • Dothan, Alabama + 70 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution, Vibrating Mesh Nebulizer, Metered Dose Inhaler, Jet Nebulizer; Drug · Device
Lead sponsor: Polarean, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Asthma
Interventions: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg, Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg, Albuterol sulfate metered-dose inhaler 180 μg; Combination Product · Drug
Lead sponsor: Bond Avillion 2 Development LP; Industry
Eligibility: 4 Years and older
Enrollment: 3,132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 170
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 139 more

Conditions: Diabetes Mellitus, Insulin-Dependent
Interventions: Insulin pump therapy, Multiple daily injections using insulin glargine + rapid acting analog; Device · Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 12 Years to 17 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: GFF MDI, GP MDI, FF MDI, Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®), Placebo MDI; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 2,103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 121
States / cities: Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 118 more

Conditions: Chronic Obstructive Pulmonary Disorder
Interventions: BFF MDI (PT009) 320/9.6 μg, BFF MDI (PT009) 160/9.6 μg, FF MDI (PT005) 9.6 μg; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 1,876 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 121
States / cities: Dothan, Alabama • Huntsville, Alabama • Sheffield, Alabama + 107 more

Conditions: Diabetes
Interventions: Insulin Guidance Software; Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 60 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: PT001 MDI, Tiotropium Bromide, PT001 Placebo MDI; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 10
States / cities: Fullerton, California • Clearwater, Florida • Panama City, Florida + 7 more

Conditions: Asthma
Interventions: Combivent CFC MDI, Albuterol HFA MDI, Respimat Combivent; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 41
States / cities: Birmingham, Alabama • Los Angeles, California • Palmdale, California + 36 more

Conditions: Cystic Fibrosis-related Diabetes
Interventions: iLet Bionic Pancreas System (BP), Usual Care (UC); Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 14 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 16
States / cities: Aurora, Colorado • New Haven, Connecticut • Atlanta, Georgia + 13 more

Conditions: Asthma
Interventions: Fp MDPI, FS MDPI, Advair Diskus, Albuterol; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 10
States / cities: Denver, Colorado • North Dartmouth, Massachusetts • St Louis, Missouri + 7 more

Conditions: Asthma
Interventions: Ciclesonide (XRP1526); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 708 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Asthma
Interventions: Albuterol Sulfate, Interferon gamma-primed mesenchymal stromal cells (MSCs), Prednisone; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Asthma
Interventions: Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 160/180 μg (high dose), Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 80/180 μg (low dose), Budesonide metered dose inhaler / BD MDI 160 µg, Albuterol sulfate metered dose inhaler / AS MDI 180 μg, Placebo metered-dose inhaler / Placebo MDI; Combination Product · Drug · Other
Lead sponsor: Bond Avillion 2 Development LP; Industry
Eligibility: 4 Years and older
Enrollment: 1,001 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 73
States / cities: Mobile, Alabama • Bakersfield, California • Costa Mesa, California + 60 more

Conditions: Healthy Participants
Interventions: Treatment A: BGF MDI HFO, Treatment B: BGF MDI HFA; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: PT003, PT001, PT005, Tiotropium inhalation powder; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 19
States / cities: Glendale, Arizona • Rancho Mirage, California • Waterbury, Connecticut + 14 more

Search by objective public record fields.

Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients

PT003 MDI Dose Confirmation Study

Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma

A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Virtual Teach-to-Goal Education vs. Brief Education for Children

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

The Pediatric Artificial Pancreas (PEDAP) Trial of Control-IQ Technology in Young Children in Type 1 Diabetes

Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD

Comparison of Bronchodilator Response From Three Different Aerosol Delivery Methods in Patients With COPD Using Hyperpolarized Xe 129 MRI Ventilation Imaging

A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma

Insulin Pump Therapy in Adolescents With Newly Diagnosed Type 1 Diabetes (T1D)

Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)

A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)

Improved Glycemic Control in Adult Subjects With Type 1 Diabetes on MDI Using Insulin Guidance Software

PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD

4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma

Bionic Pancreas in CFRD

Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects

Efficacy of Ciclesonide vs Placebo Administered as Once Daily or Twice Daily in Patients Not Treated With Inhaled Corticosteroid.

Mechanisms of Interferon Gamma-primed Mesenchymal Stromal Cells (MSCs) for Moderate-to-severe Persistent Asthma

A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma

A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults

Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease